Get started
Author

Toby Talbot

Observed names: T. Talbot, Toby Laurence James Talbot
ORCID: 0000-0002-4658-4115
Observed ORCID: 0000-0002-4658-4115
OpenAlex ID: A5034672144
Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
2018 · Michele Maio, Michele Maio, et al. · The Lancet Oncology · 216
First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study
2023 · Siow Ming Lee, Christian Schulz, et al. · The Lancet · 168
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial
2015 · M. Schuler, J.C.-H. Yang, et al. · Annals of Oncology · 131
PDF
SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
2023 · H. Borghaei, F. de Marinis, et al. · Annals of Oncology · 103
PDF
Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial
2018 · P.G. Corrie, P.G. Corrie, et al. · Annals of Oncology · 68
PDF
Ipilimumab in the real world
2015 · Saif S. Ahmad, Wendi Qian, et al. · Melanoma Research · 52
Stratification of PD-1 blockade response in melanoma using pre- and post-treatment immunophenotyping of peripheral blood
2023 · Natalie M Edner, Elisavet Ntavli, et al. · Immunotherapy Advances · 11
PDF
Efficacy of carboplatin–etoposide rechallenge after first-line chemo-immunotherapy in ES-SCLC: an international multicentric analysis
2024 · Igor Gomez-Randulfe, Sofía Silva Díaz, et al. · Therapeutic Advances in Medical Oncology · 10
A Multicentre Retrospective Analysis of Toxicity in 6-weekly Versus 3-weekly Pembrolizumab
2021 · Michael Rowe, Leonie Eastlake, et al. · Journal of Immunotherapy · 10
Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743
2026 · Arnaud Scherpereel, Paul Baas, et al. · Journal of Clinical Oncology · 7
Ipilimumab in the real world: The U.K. expanded access programme (EAP) experience in advanced melanoma.
2013 · Saif Ahmad, Wendi Qian, et al. · Journal of Clinical Oncology · 5
Brief Report: Post Hoc Validation of Platinum Ineligibility in NSCLC From the Phase III IPSOS Study
2025 · Solange Peters, Christian Schulz, et al. · Journal of Thoracic Oncology · 4
1129P Clinical outcomes from a tebentafusp UK expanded access program in patients with metastatic uveal melanoma (mUM)
2024 · P. Nathan, J.N. Tharakan, et al. · Annals of Oncology · 4
The burden of neutropenic sepsis in patients with advanced non-small cell lung cancer treated with single-agent docetaxel: A retrospective study
2017 · Toby Talbot, Adam Dangoor, et al. · Lung Cancer · 4
PDF
Service Improvements and Workload Increases: Royal College of Radiologists (RCR) Re-Audit of Curative Intent Radiotherapy for Non-Small Cell Lung Cancer (NSCLC)
2024 · J. McAleese, K. Drinkwater, et al. · Clinical Oncology · 3
CODAK: Real-World Clinical Outcomes of Patients With Unresectable, Stage III Non–Small Cell Lung Cancer Treated With Durvalumab After Chemoradiotherapy in the United Kingdom
2025 · K. Franks, D. Smith, et al. · Clinical Oncology · 2
IPSOS: A Phase III, Global, Multicentre, Open-Label, Randomised, Controlled Study of First-Line Atezolizumab Versus Single-Agent Chemotherapy in Patients with Non-Small Cell Lung Cancer Ineligible for Treatment with a Platinum-Containing Regimen
2022 · Siow-Ming Lee, Christian Schulz, et al. · SSRN Electronic Journal · 2
Abstract 7147: Ultra-high throughput single-nuclei RNAs sequencing of malignant pleural mesothelioma samples in the BEAT-MESO clinical trial
2025 · Daria Buszta, Maxim Norkin, et al. · Cancer Research · 1
CPC06 The proof is in the ink: granulomatous tattoo reaction secondary to BRAF and MEK inhibition
2024 · Emma Porter, Aaron Gould, et al. · British Journal of Dermatology · 1
Treatment patterns and clinical outcomes in patients with loco-regional recurrent melanoma in the United Kingdom
2026 · Alexandra Pender, Alison Booth, et al. · BMC Cancer
Real-world efficacy and toxicity of tebentafusp in metastatic uveal melanoma patients treated on the United Kingdom expanded access programme
2026 · Magdalene Joseph, Jacob Tharakan, et al. · The Oncologist
PDF
Clinically relevant recurrence of basal cell carcinoma following primary treatment with hypofractionated kilovoltage radiotherapy: a single-centre retrospective review
2026 · Emma M I Porter, Chloe White, et al. · British Journal of Dermatology
Abstract 2711: Large-scale integration of single-nuclei and spatial transcriptomics from the ETOP BEAT-meso trial reveals clinically relevant heterogeneity in malignant pleural mesothelioma.
2026 · Daria Buszta, Jonathan Bac, et al. · Cancer Research
A plain language summary of atezolizumab compared with single-agent chemotherapy in participants with non-small cell lung cancer who should not receive platinum-based chemotherapy (the IPSOS study)
2025 · Siow Ming Lee, Christian Schulz, et al. · Future Oncology
PDF
78 Clinical outcomes in patients with unresectable stage III Non-Small Cell Lung Cancer (NSCLC) treated with durvalumab after chemoradiation in the United Kingdom: CODAK real-world study (NCT04667312)
2024 · Kevin Franks, Daniel Smith, et al. · Lung Cancer
Works count: 30
Citation count: 802
H-index: 9
I10-index: 9
Year
Topic
Type